All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
On November 26, 2020, a press release on topline results from a phase II trial (NCT03823352) of antroquinonol in adult patients with acute myeloid leukemia (AML) was released, showing encouraging overall response rates and a safe tolerability profile.1
Based on these results, plans for future trials of antroquinonol in the frontline AML setting are ongoing and may expand to other indications, such as multiple myeloma, chronic myelogenous leukemia, and pediatric leukemia.1
Venetoclax for the treatment of AML: Developments and progress in 2020
Venetoclax (Ven) was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia in January, 2016. Since then, it has...
CPX-351 in combination with venetoclax: A phase II study in patients with R/R or newly diagnosed AML
Although there is a plethora of chemotherapeutic agents for the treatment of acute myeloid leukemia (AML), a number of patients relapse, suggesting...
Subscribe to get the best content related to AML delivered to your inbox